secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2022-04-27T23:59:59+00:00
Accession:  0001683168-22-002961
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences in-licenses DNase oncology platform from CLS Therapeutics for $500K cash + 875K shares + milestones
--------------------------------------------------------------------------------

- Upfront payment: $500K cash + 875,000 common shares (250,000 issued to OPKO per third-party obligation).
- Milestone payments up to $13M per program in cash plus up to 950,000 additional shares for regulatory milestones.
- Licensed platform includes systemic DNase (co-admin with chemo/IO) and DNase-armored CAR T therapies.
- Xenetic plans Phase 1 study of lead asset in locally advanced or metastatic solid tumors.
- Tiered royalties on net sales (mid-single to low-double digits); sublicense revenue share in mid-teens to low-double digits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822002961/0001683168-22-002961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822002961/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-002961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer